Patents by Inventor Mark E. Reynolds

Mark E. Reynolds has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD FOR MANUFACTURING A BORONIC ACID ESTER COMPOUND
    Publication number: 20120123122
    Abstract: The present invention relates to a method for manufacturing a boronic acid ester compound, characterized by reacting an aryl halide compound and a diboron ester compound in the presence of a nitrogen-containing organic base, a nickel catalyst, a phosphine compound and a solvent. According to the manufacturing method of the present invention, even if a nickel catalyst is used as the catalyst, a desired boronic acid ester compound can be obtained in a sufficiently high yield. Furthermore, even if aryl chloride or aryl bromide having relatively low price and low reactivity, was used as the aryl halide compound, a desired boronic acid ester compound can be obtained in a sufficiently high yield.
    Type: Application
    Filed: March 24, 2009
    Publication date: May 17, 2012
    Applicants: GENENTECH, INC., SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventors: Takashi Miki, Yasuharu Shimasaki, Srinivasan Babu, Zhigang Cheng, Mark E. Reynolds, Qingping Tian
  • PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING
    Publication number: 20120094980
    Abstract: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.
    Type: Application
    Filed: October 14, 2011
    Publication date: April 19, 2012
    Inventors: Janet L. Gunzner, Daniel P. Sutherlin, Mark S. Stanley, Liang Bao, Georgette Castanedo, Rebecca Lalonde, Shumei Wang, Mark E. Reynolds, Scott J. Savage, Kimberly Malesky, Michael S. Dina, Michael F.T. Koehler
  • PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING
    Publication number: 20110092461
    Abstract: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.
    Type: Application
    Filed: December 6, 2010
    Publication date: April 21, 2011
    Inventors: Janet L. GUNZNER, Daniel Sutherlin, Mark S. Stanley, Liang Bao, Georgette M. Castanedo, Rebecca L. Lalonde, Shumei Wang, Mark E. Reynolds, Scott J. Savage, Kimberly Malesky, Michael S. Dina
  • NEMORUBICIN METABOLITE AND ANALOG REAGENTS, ANTIBODY-DRUG CONJUGATES AND METHODS
    Publication number: 20110076287
    Abstract: The present invention relates to antibody-drug conjugate compounds of Formula I: Ab-(L-D)p??I where one or more nemorubicin metabolite or analog drug moieties (D) are covalently attached by a linker (L) to an antibody (Ab) which binds to one or more tumor-associated antigens or cell-surface receptors. These compounds may be useful in methods of diagnosis or treatment of cancer, and other diseases and disorders.
    Type: Application
    Filed: January 16, 2009
    Publication date: March 31, 2011
    Inventors: Robert L Cohen, Edward HyungSuk Ha, Mark E. Reynolds
  • Pyridyl inhibitors of hedgehog signalling
    Patent number: 7888364
    Abstract: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.
    Type: Grant
    Filed: September 2, 2005
    Date of Patent: February 15, 2011
    Assignee: Curis, Inc.
    Inventors: Janet L. Gunzner, Daniel Sutherlin, Mark S. Stanley, Liang Bao, Georgette M. Castanedo, Rebecca L. Lalonde, Shumei Wang, Mark E. Reynolds, Scott J. Savage, Kimberly Malesky, Michael S. Dina
  • PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS
    Publication number: 20100292468
    Abstract: The invention provides processes of preparing, separating, and purifying PI3K inhibitor, Formula (I) and (II) compounds, and novel intermediates for preparing Formula (I) and (II) compounds.
    Type: Application
    Filed: October 24, 2008
    Publication date: November 18, 2010
    Inventors: Srinivasan Babu, Zhigang Cheng, Mark E. Reynolds, Scott J. Savage, Qingping Tian, Herbert Yajima
  • PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING
    Publication number: 20090281089
    Abstract: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.
    Type: Application
    Filed: April 8, 2009
    Publication date: November 12, 2009
    Applicant: Genentech, Inc.
    Inventors: Janet L. Gunzner, Daniel P. Sutherlin, Mark S. Stanley, Liang Bao, Georgette Castanedo, Rebecca L. LaLonde, Shumei Wang, Mark E. Reynolds, Scott J. Savage, Kimberly Malesky, Michael S. Dina
  • Integrin receptor inhibitors
    Patent number: 7265146
    Abstract: Provided are compounds of formula (I) wherein A, Q, W, X, Y, Z, R1 to R4, m and n are as defined herein. Compounds of the invention bind to ?4 integrin receptors and thereby inhibit binding of ligands for ?4 integrins which is useful for prophylactic and/or therapeutic treatment of diseases and conditions associated with ?4 integrins or their ligands.
    Type: Grant
    Filed: April 20, 2005
    Date of Patent: September 4, 2007
    Assignee: Genentech, Inc.
    Inventors: Dean R. Artis, David Y. Jackson, Thomas E. Rawson, Mark E. Reynolds, Daniel P. Sutherlin, Mark S. Stanley
  • IgE receptor antagonists
    Patent number: 7101851
    Abstract: The invention provides novel compounds which bind to the high affinity receptor for immunoglobulin E (IgE) designated Fc?RI and methods for identifying and preparing such compounds. In particular aspects, the invention provides to the treatment of disorders mediated by IgE utilizing the novel compounds of the invention. The invention also provides composition, such as pharmaceutical compositions, comprising the novel compounds, as well as for their use in research, diagnostic, therapeutic, and prophylactic methods.
    Type: Grant
    Filed: September 26, 2001
    Date of Patent: September 5, 2006
    Assignee: Genentech, Inc.
    Inventors: Henry B. Lowman, Gerald R. Nakamura, Mark E. Reynolds, Melissa A. Starovasnik
  • Integrin receptor inhibitors
    Patent number: 6933314
    Abstract: Provided are compounds of formula (I) wherein A, Q, W, X, Y, Z, R1 to R4, m and n are as defined herein. Compounds of the invention bind to ?4 integrin receptors and thereby inhibit binding of ligands for ?4 integrins which is useful for prophylactic and/or therapeutic treatment of diseases and conditions associated with ?4 integrins or their ligands.
    Type: Grant
    Filed: September 30, 2003
    Date of Patent: August 23, 2005
    Assignee: Genentech, Inc.
    Inventors: Dean R. Artis, David Y. Jackson, Thomas E. Rawson, Mark E. Reynolds, Daniel P. Sutherlin, Mark S. Stanley
  • LFA-1 antagonist compounds
    Patent number: 6872735
    Abstract: The invention relates to novel compounds having formula (I) wherein Cy, X, Y, L and R1-6 are as defined herein. The compounds bind CD11/CD18 adhesion receptors such as Lymphocyte Function-associated Antigen-1 (LFA-1) and are therefore useful for treating disorders mediated by LFA-1 such as inflammation and autoimmune diseases.
    Type: Grant
    Filed: July 11, 2003
    Date of Patent: March 29, 2005
    Assignee: Genentech, Inc.
    Inventors: Daniel J. Burdick, Mark S. Stanley, David Oare, Mark E. Reynolds, Thomas R. Gadek, James C. Marsters
  • Ige receptor antagonists
    Publication number: 20040086942
    Abstract: The invention provides novel compounds which bind to the high affinity receptor for immunoglobulin E (IgE) designated Fc&egr;RI and methods for identifying and preparing such compounds. In particular aspects, the invention provides to the treatment of disorders mediated by IgE utilizing the novel compounds of the invention. The invention also provides compositions, such as pharmaceutical compositions, comprising the novel compounds, as well as for their use in research, diagnostic, therapeutic, and prophylactic methods.
    Type: Application
    Filed: March 20, 2003
    Publication date: May 6, 2004
    Inventors: Henry B Lowman, Gerald R Nakamura, Mark E Reynolds, Melissa A Starovasnik
  • Integrin receptor inhibitors
    Publication number: 20040077693
    Abstract: Provided are compounds of formula (I) 1
    Type: Application
    Filed: September 30, 2003
    Publication date: April 22, 2004
    Applicant: Genentech, Inc.
    Inventors: Dean R. Artis, David Y. Jackson, Thomas E. Rawson, Mark E. Reynolds, Daniel P. Sutherlin, Mark S. Stanley
  • LFA-1 antagonist compounds
    Publication number: 20040058968
    Abstract: The invention relates to novel compounds having formula (I) 1
    Type: Application
    Filed: July 11, 2003
    Publication date: March 25, 2004
    Applicant: Genentech, Inc.
    Inventors: Daniel J. Burdick, Mark S. Stanley, David Oare, Mark E. Reynolds, Thomas R. Gadek, James C. Marsters
  • Integrin receptor inhibitors
    Patent number: 6706753
    Abstract: Provided are compounds of formula (I) wherein A, Q, W, X, Y, Z, R1 to R4, m and n are as defined herein. Compounds of the invention bind to &agr;4 integrin receptors and thereby inhibit binding of ligands for &agr;4 integrins which is useful for prophylactic and/or therapeutic treatment of diseases and conditions associated with &agr;4 integrins or their ligands.
    Type: Grant
    Filed: December 6, 2002
    Date of Patent: March 16, 2004
    Assignee: Genentech, Inc.
    Inventors: Dean R. Artis, David Y. Jackson, Thomas E. Rawson, Mark E. Reynolds, Daniel P. Sutherlin, Mark S. Stanley
  • LFA-1 antagonist compounds
    Patent number: 6667318
    Abstract: The invention relates to novel compounds having formula (I) wherein Cy, X, Y, L and R1-6 are as defined herein. The compounds bind CD11/CD18 adhesion receptors such as Lymphocyte Function-associated Antigen-1 (LFA-1) and are therefore useful for treating disorders mediated by LFA-1 such as inflammation and autoimmune diseases.
    Type: Grant
    Filed: November 26, 2001
    Date of Patent: December 23, 2003
    Assignee: Genentech, Inc.
    Inventors: Daniel J. Burdick, Mark S. Stanley, David Oare, Mark E. Reynolds, Thomas R. Gadek, James C. Marsters
  • Integrin receptor inhibitors
    Publication number: 20030100599
    Abstract: Provided are compounds of formula (I) 1
    Type: Application
    Filed: December 6, 2002
    Publication date: May 29, 2003
    Applicant: Genentech, Inc.
    Inventors: Dean R. Artis, David Y. Jackson, Thomas E. Rawson, Mark E. Reynolds, Daniel P. Sutherlin, Mark S. Stanley
  • LFA-1 Antagonist compounds
    Publication number: 20020119994
    Abstract: The invention relates to novel compounds having formula (I) 1
    Type: Application
    Filed: November 26, 2001
    Publication date: August 29, 2002
    Applicant: GENENTECH, INC
    Inventors: Daniel J. Burdick, Mark S. Stanley, David Oare, Mark E. Reynolds, Thomas R. Gadek, James C. Marsters
  • Integrin receptor inhibitors
    Publication number: 20020035104
    Abstract: Provided are compounds of formula (I) 1
    Type: Application
    Filed: August 16, 2001
    Publication date: March 21, 2002
    Applicant: GENENTECH, INC.
    Inventors: Dean R. Artis, David Y. Jackson, Thomas E. Rawson, Mark E. Reynolds, Daniel P. Sutherlin, Mark S. Stanley